Across TCGA pan-cancer cohorts, RNASE9 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RNASE9 data layer compared with 11 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher RNASE9 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RNASE9 expression acts as an unfavorable survival marker.

OV, SKCM, and LUAD are the cancer types where RNASE9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.180	0.844	<.001	36	view →
SKCM	OS	Median	III,IV	0.430	0.807	<.001	20	view →
LUAD	DFS	Median	All	0.178	0.813	<.001	18	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: RNASE9 tumor-vs-normal RNA expression · all RNASE9 data types